Categories Health Care, IPO
IPO News: Everything you need to know about BioAge Labs’ IPO
The management has applied to list the stock on Nasdaq under the symbol BIOA
BioAge Labs, Inc. is the latest among the healthcare companies pursuing stock-market listing this year. In a registration statement filed with the Securities and Exchange Commission, the company revealed plans to offer around 7.5 million common shares in an initial public offering. The estimated offer price is between $17.0 per share and $19.0 per share.
The company has applied to list on the Nasdaq Global Market under the symbol BIOA. Goldman Sachs, Morgan Stanley, Jefferies, and Citigroup are the bookrunners in the offering. The estimated net proceeds from this offering and the concurrent private placement are expected to be around $134.5 million, based on the midpoint of the price range.
The BioAge leadership plans to use the proceeds mainly to advance the development of azelaprag, the lead product candidate being developed for the treatment of obesity. A part of the proceeds will be used for working capital and other general corporate purposes.
The Company
BioAge is a clinical-stage biopharmaceutical company engaged in the development of therapeutic product candidates for metabolic diseases like obesity, by targeting the biology of human aging. In preclinical tests, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like peptide-1 receptor agonist. It also restored healthy body composition and improved muscle function.
Currently, the company is developing a pipeline of platform-derived therapeutics for the treatment of chronic metabolic disease. Azelaprag is an orally available small-molecule agonist of the apelin receptor where the activation has the potential to recapitulate many of the benefits of exercise. The drug is being developed in combination with GLP-1R agonists to augment overall weight loss, with the potential to also improve tolerability and body composition.
Key Numbers
For the year ended December 2023, BioAge reported a comprehensive loss of $63.9 million, compared to a loss of $39.5 million in the previous year. Full-year research and development expenses increased 11% year-over-year to $33.9 million. In the six months ended June 30, 2024, loss narrowed modestly to $26.6 million from $28.2 million in the corresponding period of 2023. At $19.8 million, research and development expenses were up 15% year-over-year during the six months.
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Costco (COST) reports strong growth in Q1 FY26 earnings; revenue up 8%
Costco Wholesale Corporation (NASDAQ: COST) has reported an increase in net income for the first quarter of fiscal 2026. Revenues grew 8.3% year-over-year. The Issaquah, Washington-headquartered warehouse giant’s total revenues
AVGO Earnings: Broadcom reports higher Q4 FY25 revenue, profit; results beat
Semiconductor company Broadcom, Inc. (NASDAQ: AVGO) on Thursday reported an increase in revenue and adjusted earnings for the fourth quarter of fiscal 2025. The numbers also surpassed analysts' expectations. Adjusted
Lamb Weston (LW) is set to report Q2 2026 earnings next week, here’s what to look for
Shares of Lamb Weston Holdings, Inc. (NYSE: LW) rose over 1% on Thursday. The stock has gained 4% over the past three months. The French fry giant is slated to
